Controled Ovarian Stimulation with Urinary Gonadotrophins and Recombinant Gonadotrophins in Current Practice

Claudia Mehedintu,Alina Bordea,Adrian Gheorghe Bumbu,Diana Elena Comandasu,Elvira Bratila,Monica Mihaela Cirstoiu,Cristian Sava,Ovidiu Bratu,Lacramioara Aurelia Brinduse,Andreea Carp Veliscu,Costin Berceanu

doi:10.37358/rc.18.12.6803

Abstract

The main objective of the this study is to compare the effectiveness of ovarian stimulation with recombinant gonadotrophins (FSHr) versus urinary gonadotrophins (hMG) within the number of oocytes obtained and the number of embryos in the two patient groups, according to age groups and associated pathologies. The study design was retrospective, monocentric. All patients (71) who have addressed the In Vitro Fertilization Clinic of the Prof. Dr. Panait Sirbu Clinical Obstetrics and Gynecology Hospital during 01.01.2010 and 31.12.2010 were included in this research. The total number of oocytes (8.5�3.9 vs 5.7�3.9, p=0.045), the number of fertilized oocytes (7.5�3.6 versus 3.6�2.8 p=0.004) and the number of embryos (6.6�3.5 versus 3.7�2.6, p=0.013) were higher in women under 35 years of age treated with recombinant FSHr compared to women treated with urinary gonadotrophins hMG. Ovarian stimulation with recombinant gonadotrophins provides a greater number of oocytes and a greater number of embryos in all patients, regardless of age and associated pathology. There are many variables that can influence the success rate, but the first variable that can be controlled is the choice of FSHr in daily clinical practice.

Highlights

The main objective of the this study is to compare the effectiveness of ovarian stimulation with recombinant gonadotrophins (FSHr) versus urinary gonadotrophins within the number of oocytes obtained and the number of embryos in the two patient groups, according to age groups and associated pathologies
Assisted Human Reproduction (ART) is a science that many practitioners compare with an art because the choice of stimulation protocols and drugs according to the particularity of each infertility case requires experience and a clinical sense, which are not found in standardized protocols
The therapeutic approach varies between clinics, and the choice of ovarian stimulation drugs often depends on the clinician’s experience with a particular product, as well as the results previously obtained in similar cases

Summary

Introduction

The main objective of the this study is to compare the effectiveness of ovarian stimulation with recombinant gonadotrophins (FSHr) versus urinary gonadotrophins (hMG) within the number of oocytes obtained and the number of embryos in the two patient groups, according to age groups and associated pathologies. Age and ovarian reserve (assessed by AMH serum anti-Mullerian hormone or AFC - antral follicle count) cannot be changed [1,2,3] and are the only ones that provide an idea of the number of oocytes that could be harvested even before ovarian stimulation beginning Starting from these two constants (age and ovarian reserve) that cannot be changed, each clinician chooses a stimulation protocol in favor of another, as well as the optimal dose of gonadotrophins for each patient [4,5,6,7]. Substances used for stimulation are urinary or recombinant FSH, urinary or recombinant FSH and LH

Objectives

Results

Conclusion